SCHEMBL16633268

SCHEMBL16633268

CCC(O)(CC)C(c1ccc(OC(F)(F)F)cc1)N(C(=O)O)C(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.39
HDAC3 O15379 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC2 Q92769 1/20 0.38
EPHX2 P34913 2/20 0.38
PPARG P37231 2/20 0.38
PPARA Q07869 2/20 0.38
NR1H4 Q96RI1 1/20 0.38
PDE2A O00408 3/20 0.37
POLB P06746 1/20 0.37
TRPV1 Q8NER1 1/20 0.37
HRH3 Q9Y5N1 2/20 0.36
PSEN1 P49768 1/20 0.36
PSEN2 P49810 1/20 0.36
SPPL2B Q8TCT7 1/20 0.36
SPPL2A Q8TCT8 1/20 0.36
APH1B Q8WW43 1/20 0.36
NCSTN Q92542 1/20 0.36
APH1A Q96BI3 1/20 0.36
PSENEN Q9NZ42 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16563726 0.87 TRPV1 (0.40) ALDH1A1EPHX2NR1H4PDE2ATRPV1
SCHEMBL16633449 0.79 ALDH1A1 (0.39) ALDH1A1HDAC3HDAC1HDAC2EPHX2
SCHEMBL16633980 0.78 ALDH1A1 (0.41) ALDH1A1EPHX2PPARANR1H4PDE2A
SCHEMBL16634078 0.77 EPHX1 (0.40) ALDH1A1EPHX2NR1H4PDE2APOLB
SCHEMBL16633204 0.76 MMP2 (0.40) ALDH1A1PDE2APOLBPSEN1PSEN2
SCHEMBL16633233 0.75 EPHX1 (0.43) ALDH1A1EPHX2PPARGPPARAPDE2A
SCHEMBL16632995 0.75 EPHX1 (0.41) ALDH1A1EPHX2PPARGPPARANR1H4
SCHEMBL16633394 0.74 ALDH1A1 (0.38) ALDH1A1EPHX2PPARGPPARAPDE2A
SCHEMBL16633417 0.74 ALDH1A1 (0.38) ALDH1A1EPHX2PPARGPPARAPDE2A
SCHEMBL16633428 0.74 ALDH1A1 (0.38) ALDH1A1EPHX2PPARGPPARANR1H4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9469637-B2 Nitrogenated heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-10-18 US disclosed
US-20150105373-A1 NITROGENATED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150105373-A1 NITROGENATED HETEROCYCLIC COMPOUND PDE2A, PDE5A, PDE3A ALDH1A1 492/4885HDAC3 1409/4885HDAC1 141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.